title: The effects of post-exposure smallpox vaccination on clinical disease presentation: addressing the data gaps between historical epidemiology and modern surrogate model data.
abstract: Decades after public health interventions - including pre- and post-exposure vaccination - were used to eradicate smallpox, zoonotic orthopoxvirus outbreaks and the potential threat of a release of variola virus remain public health concerns. Routine prophylactic smallpox vaccination of the public ceased worldwide in 1980, and the adverse event rate associated with the currently licensed live vaccinia virus vaccine makes reinstatement of policies recommending routine pre-exposure vaccination unlikely in the absence of an orthopoxvirus outbreak. Consequently, licensing of safer vaccines and therapeutics that can be used post-orthopoxvirus exposure is necessary to protect the global population from these threats. Variola virus is a solely human pathogen that does not naturally infect any other known animal species. Therefore, the use of surrogate viruses in animal models of orthopoxvirus infection is important for the development of novel vaccines and therapeutics. Major complications involved with the use of surrogate models include both the absence of a model that accurately mimics all aspects of human smallpox disease and a lack of reproducibility across model species. These complications limit our ability to model post-exposure vaccination with newer vaccines for application to human orthopoxvirus outbreaks. This review seeks to (1) summarize conclusions about the efficacy of post-exposure smallpox vaccination from historic epidemiological reports and modern animal studies; (2) identify data gaps in these studies; and (3) summarize the clinical features of orthopoxvirus-associated infections in various animal models to identify those models that are most useful for post-exposure vaccination studies. The ultimate purpose of this review is to provide observations and comments regarding available model systems and data gaps for use in improving post-exposure medical countermeasures against orthopoxviruses.
authors.affiliation: Centers for Disease Control and Prevention, Division of High-Consequence Pathogens and Pathology, Poxvirus and Rabies Branch, United States. Electronic address: hbq0@cdc.gov.
authors.forename: M Shannon
authors.initials: MS
authors.lastname: Keckler
authors.forename: Mary G
authors.initials: MG
authors.lastname: Reynolds
authors.forename: Inger K
authors.initials: IK
authors.lastname: Damon
authors.forename: Kevin L
authors.initials: KL
authors.lastname: Karem
mesh_terms: D000818:Animals; D004195:Disease Models, Animal; D006801:Humans; D056990:Post-Exposure Prophylaxis / Q000379:methods*; D012899:Smallpox / Q000473:pathology* / Q000517:prevention & control*; D012900:Smallpox Vaccine / Q000008:administration & dosage*; D014611:Vaccination / Q000379:methods*
chemical_list: D012900:Smallpox Vaccine
keywords: Animal models; Epidemiology; Monkeypox; Orthopoxviruses; Post-exposure vaccination; Prophylactic vaccination; Smallpox; Smallpox vaccination; Vaccinia; Variola virus